Pleural Effusion, Malignant Clinical Trial
Official title:
Single-arm Open Multicenter Study of IFN-γ Combined With T Cells in the Treatment of Refractory Malignant Pleural Effusion Tumors
The purpose of this study was to evaluate the efficacy of IFN- Y combined with T cells in the treatment of refractory malignant pleural effusion and acties, using a multicenter, single-arm, open design.
Malignant pleural effusion is a common complication of malignant tumor, which usually indicates that the patient has reached the advanced stage, and about 30-40% of the patients are stubborn and refractory cases. The lack of standard therapeutic drugs and protocols in clinical practice seriously affects the anti-tumor treatment effect, quality of life and survival time of patients, and the prognosis is poor. IFN-γ can significantly induce the high expression of the costimulatory molecule ICAM-1 on tumor cells, thereby enhancing the killing of TUMOR cells by T cells. Moreover, IFN-γ can enhance the activity of CAR T cells in the presence of PD-L1-PD-1 pathway, and significantly improve the therapeutic effect of T cells on solid tumors. IFN-γ is an approved clinical treatment with known side effects and well-established symptomatic treatment. Although CIK is not a clinically approved drug, it has been used on a large scale in China with good safety and has entered the medical insurance of some provinces and cities. Tcm is an improved CIK cell and has good safety. Many clinical studies have been carried out, and no serious toxic and side effects have been observed. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT05693727 -
Cancer Ratio,Pleural Fluid Adenosine Deaminase,Lactate Dehydrogenase, interferonY, Tumor Necrosis Factor,and Interleukins{2,12,18}for Differentiation Between Malignant and Non Malignant Pleural Effusion
|
||
| Recruiting |
NCT05910112 -
Prospective Data Collection on Clinical, Radiological and Patient Reported Outcomes After Pleural Intervention
|
||
| Completed |
NCT03270215 -
The Added Value of CT Scanning in Patients With an Unilateral Pleural Effusion
|
||
| Completed |
NCT03272997 -
The Value of PET-CT in Pleural Effusions
|
||
| Completed |
NCT00099541 -
Non-small Cell Lung Cancer Registry
|
Phase 4 | |
| Recruiting |
NCT04844827 -
Pleural Carcinomatosis Tissue Banking
|
||
| Not yet recruiting |
NCT06436807 -
PMCF Study of the CE-marked Drainova® ArgentiC Catheter
|
||
| Recruiting |
NCT05278975 -
Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT02407912 -
Cisplatin for Malignant Pleural Effusion in Patients With Non-small-cell Lung Cancer
|
N/A | |
| Terminated |
NCT00316134 -
Multiple Biomarkers in Undiagnosed Pleural Effusion
|
N/A | |
| Not yet recruiting |
NCT06275178 -
Medical Thoracoscopy for Diagnosing Unexplained Pleural Effusion: a National Multicenter Retrospective Study
|
||
| Recruiting |
NCT04684459 -
Dual-targeting HER2 and PD-L1 CAR-T for Cancers With Pleural or Peritoneal Metastasis
|
Early Phase 1 | |
| Recruiting |
NCT04670562 -
Longitudinal Follow up of Patients With Pleural Effusion
|
||
| Not yet recruiting |
NCT02805062 -
Manometry vs Clinical Assessment in the Detection of Trapped Lung in Patients With Suspected Pleural Malignancy
|
N/A | |
| Completed |
NCT03276715 -
Prognostic Factors on Malignant Pleural Effusion
|
||
| Completed |
NCT03394105 -
Intrapleural Docetaxel Administration Using Medical Pleuroscopy in Malignant Effusion With Lung Cancer
|
Phase 2 | |
| Recruiting |
NCT05461430 -
Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
|
||
| Terminated |
NCT02702700 -
Photo-induction as a Means to Improve Cisplatin Delivery to Pleural Malignancies
|
Phase 1 | |
| Recruiting |
NCT02045121 -
Multicentre Study Comparing Indwelling Pleural Catheter With Talc Pleurodesis for Malignant Pleural Effusion Management
|
N/A | |
| Completed |
NCT01670786 -
Safety Profile of Iodopovidone as an Agent for Pleurodesis in Malignant Pleural Effusion
|
Phase 4 |